Lucy V Cobbs1, Jasmine H Francis1,2, Ira J Dunkel3,4, Y Pierre Gobin1,5, Scott E Brodie6, David H Abramson1,2. 1. Ophthalmic Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Ophthalmology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York. 3. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Pediatrics, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York. 5. Interventional Neuroradiology, Department of Neurosurgery, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York. 6. Department of Ophthalmology, NYU Langone Health, New York, New York.
Abstract
BACKGROUND: This study aimed to identify best practices for treating 13q deletion syndrome (13q-) patients with retinoblastoma in the era of super-selective ophthalmic artery chemosurgery (OAC) and intravitreal injection therapy (IVIT). METHODS: Retrospective study of 21 eyes from 14 patients with retinoblastoma and 13q- who were treated at Memorial Sloan Kettering Cancer Center (MSKCC) between May 2006 and May 2020, with a mean follow up of 3.7 years. Ocular survival, patient survival, and treatment toxicities were assessed. RESULTS: Nine of the 12 eyes that underwent OAC/IVIT at MSKCC have been progression free for at least 1 year since their last treatments. Fifteen out of 26 OAC cycles resulted in grade 3-4 hematologic toxicity. There was one death from sepsis in the setting of intravenous chemotherapy (IVC) for metastatic disease that occurred after OAC/IVIT therapy. The 2-year Kaplan-Meier ocular survival estimate for the whole cohort was 75% and for the eyes that received OAC or IVIT at MSKCC 83%. For OAC hematologic toxicities, one platelet transfusion and two filgrastim doses were administered, and one patient was hospitalized for neutropenic fevers. CONCLUSIONS: The majority of 13q- eyes treated with OAC/IVIT-based regimens can be cured, and there were no deaths related to complications from OAC or IVIT. 13q- Patients did have increased risk of systemic treatment complications, even from super-selective chemotherapies. Despite these toxicities, only one patient developed febrile neutropenia, one patient required a blood product transfusion, and two patients received filgrastim for both OAC and IVC complications. PRÉCIS: Children with 13q deletion syndrome with retinoblastoma managed with intra-arterial and intravitreal chemotherapy have excellent patient and ocular survival with acceptable toxicity.
BACKGROUND: This study aimed to identify best practices for treating 13q deletion syndrome (13q-) patients with retinoblastoma in the era of super-selective ophthalmic artery chemosurgery (OAC) and intravitreal injection therapy (IVIT). METHODS: Retrospective study of 21 eyes from 14 patients with retinoblastoma and 13q- who were treated at Memorial Sloan Kettering Cancer Center (MSKCC) between May 2006 and May 2020, with a mean follow up of 3.7 years. Ocular survival, patient survival, and treatment toxicities were assessed. RESULTS: Nine of the 12 eyes that underwent OAC/IVIT at MSKCC have been progression free for at least 1 year since their last treatments. Fifteen out of 26 OAC cycles resulted in grade 3-4 hematologic toxicity. There was one death from sepsis in the setting of intravenous chemotherapy (IVC) for metastatic disease that occurred after OAC/IVIT therapy. The 2-year Kaplan-Meier ocular survival estimate for the whole cohort was 75% and for the eyes that received OAC or IVIT at MSKCC 83%. For OAC hematologic toxicities, one platelet transfusion and two filgrastim doses were administered, and one patient was hospitalized for neutropenic fevers. CONCLUSIONS: The majority of 13q- eyes treated with OAC/IVIT-based regimens can be cured, and there were no deaths related to complications from OAC or IVIT. 13q- Patients did have increased risk of systemic treatment complications, even from super-selective chemotherapies. Despite these toxicities, only one patient developed febrile neutropenia, one patient required a blood product transfusion, and two patients received filgrastim for both OAC and IVC complications. PRÉCIS: Children with 13q deletion syndrome with retinoblastoma managed with intra-arterial and intravitreal chemotherapy have excellent patient and ocular survival with acceptable toxicity.
Authors: Jasmine H Francis; Scott E Brodie; Brian Marr; Emily C Zabor; Ijah Mondesire-Crump; David H Abramson Journal: Ophthalmology Date: 2017-01-12 Impact factor: 12.079
Authors: Ana Roche; Jaume Mora; Maria Del Mar Perez; Esther Gean; Belen Perez; Mar O'Callaghan; Jaume Catala; Carmen De Torres; Ofelia Cruz; Joan Prat; Andreu Parareda Journal: Pediatr Blood Cancer Date: 2010-03 Impact factor: 3.167
Authors: H S Chan; G DeBoer; J J Thiessen; A Budning; J E Kingston; J M O'Brien; G Koren; E Giesbrecht; G Haddad; Z Verjee; J L Hungerford; V Ling; B L Gallie Journal: Clin Cancer Res Date: 1996-09 Impact factor: 12.531
Authors: Y Pierre Gobin; Ira J Dunkel; Brian P Marr; Jasmine H Francis; Scott E Brodie; David H Abramson Journal: PLoS One Date: 2012-09-18 Impact factor: 3.240
Authors: David H Abramson; Carol L Shields; Pascal Jabbour; Luiz Fernando Teixeira; José Roberto Falco Fonseca; Marcio Chaves Pedro Marques; Francis L Munier; Francesco Puccinelli; Theodora Hadjistilianou; Sandra Bracco; Guillermo Chantada; Alejandro Ceciliano; Y Pierre Gobin Journal: Int J Retina Vitreous Date: 2017-10-23
Authors: Jasmine H Francis; David H Abramson; Y Pierre Gobin; Brian P Marr; Ira J Dunkel; Elyn R Riedel; Scott E Brodie Journal: PLoS One Date: 2014-01-20 Impact factor: 3.240